Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
It is aimed specifically at fat cells with no disruption of the general hormone network
The limited human data available indicate that both peptides appear to be generally well-tolerated, yet comprehensive safety and efficacy assessments from large, well-designed clinical trials are absent
This IGF-1 independence is the single most important experimental advantage of the AOD 9604 10mg research compound for researchers designing metabolic studies: the absence of IGF-1 elevation means that downstream anabolic, mitogenic, or glucose-modulating confounds associated with full-length hGH are not present in AOD-9604 experimental models
This visual indicator can help researchers assess compound integrity, though formal verification relies on the batch-specific Certificate of Analysis
First author Dr
CJC-1295 DAC (2 mg Vial) Long-acting GHRH analog for sustained growth hormone release.
